Table 3

Summary of factors associated with choice of etanercept over monoclonal antibody TNFis in patients with axSpA (summary of separate univariable models)

VariableWaldP valueOR95% CI for OR
Gender (male vs female)3.5610.0591.3510.988–1.847
Age (years)0.8420.3590.9950.984–1.006
Disease duration (years)2.0620.1510.9920.980–1.003
BASDAI score12.226<0.0011.1461.062–1.237
BASFI score10.3930.0011.1071.041–1.178
HLA-B27 positivity0.0330.8561.0380.692–1.557
Smoking (current vs none)1.5250.2171.2680.870–1.848
Smoking (ex-smoking vs none)0.0840.7721.0540.736–1.510
Education (ordinal)3.5430.0600.8930.793–1.005
Education (university degree vs lower)4.0840.0430.7300.539–0.991
BMI (kg/m2)0.3650.5460.9560.826–1.106
AAU (any)27.943<0.0010.2940.187–0.463
AAU episodes in last 12 months9.3360.0020.4840.304–0.771)
IBD (Crohn’s disease or ulcerative colitis)13.081<0.0010.3540.201–0.621
Crohn’s disease9.4570.0020.0440.006–0.323
Ulcerative colitis7.4560.0060.1920.056–0.628
Psoriasis1.7070.1910.7380.468–1.164
  • AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; EAM, extra-articular manifestation; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; TNFi, tumour necrosis factor-inhibitor.